[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 286
Citations 0
Correction
July 13, 2020

Error in the Biomarker Subsection

JAMA Neurol. Published online July 13, 2020. doi:10.1001/jamaneurol.2020.2416

In the Original Investigation titled “Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials,” which published online November 11, 2019, and in print in February 2020 in JAMA Neurology,1 there was an error in the Biomarkers subsection of the Results section. The mean data for lanabecestat 20 mg vs placebo in DAYBREAK-ALZ was 2.2 Centiloids not −2.2 Centiloids. This article was corrected online.

×